CSBIO(SZ:300255) Jing Ji Guan Cha Wang·2026-01-12 10:14Core Insights - The case involves commercial bribery linked to the pharmaceutical industry, specifically between Haiyilai Company and Hongjian Pharmaceutical Company regarding the promotion of a drug called Danheparin Sodium Injection [1][2][4] Group 1: Company Actions - Haiyilai Company signed a one-year information service agreement with Hongjian Pharmaceutical Company to promote Danheparin Sodium Injection in Shanghai [1] - During the period from January to December 2023, Haiyilai's sales promotion director made four personal WeChat transfers totaling 35,046 yuan to a doctor to incentivize the prescription of the drug [2] - The total revenue generated by Haiyilai from the marketing and information services for Danheparin Sodium in 2023 was 868,677 yuan [2] Group 2: Regulatory Response - The Shanghai Putuo District Market Supervision Administration imposed a fine of 300,000 yuan on Haiyilai Company for commercial bribery [2] - The National Medical Insurance Administration emphasized that such bribery undermines fair competition and increases the burden on the healthcare system [4] - The case has prompted a credit evaluation process for the involved companies, including Hongjian Pharmaceutical and its supplier, Hebei Changshan Biochemical Pharmaceutical Company [2][4] Group 3: Industry Context - Hebei Changshan Biochemical Pharmaceutical Company, also known as Changshan Pharmaceutical, is a publicly listed company specializing in cardiovascular drugs and has a complete heparin product supply chain [3] - Danheparin Sodium Injection, a key product for Changshan Pharmaceutical, generated over 170 million yuan in sales annually and is used for treating various cardiovascular conditions [3] - The company plans to increase the promotion of Danheparin Sodium Injection, with a projected sales volume growth of 26.68% in 2024, although revenue is expected to remain stable due to price declines [3]